Tranexamic acid and trauma: Current status and knowledge gaps with recommended research priorities

Anthony E. Pusateri, Richard B. Weiskopf, Vikhyat Bebarta, Frank Butler, Ramon F. Cestero, Irshad H. Chaudry, Virgil Deal, Warren C. Dorlac, Robert T. Gerhardt, Michael B. Given, Dan R. Hansen, W. Keith Hoots, Harvey G. Klein, Victor W. MacDonald, Kenneth L. Mattox, Rodney A. Michael, Jon Mogford, Elizabeth A. Montcalm-Smith, Debra M. Niemeyer, W. Keith PrusaczykJoseph F. Rappold, Todd Rassmussen, Francisco Rentas, James Ross, Christopher Thompson, Leo D. Tucker

Producción científica: Review articlerevisión exhaustiva

89 Citas (Scopus)

Resumen

A recent large civilian randomized controlled trial on the use of tranexamic acid (TXA) for trauma reported important survival benefits. Subsequently, successful use of TXA for combat casualties in Afghanistan was also reported. As a result of these promising studies, there has been growing interest in the use of TXA for trauma. Potential adverse effects of TXA have also been reported. A US Department of Defense committee conducted a review and assessment of knowledge gaps and research requirements regarding the use of TXA for the treatment of casualties that have experienced traumatic hemorrhage. We present identified knowledge gaps and associated research priorities. We believe that important knowledge gaps exist and that a targeted, prioritized research effort will contribute to the refinement of practice guidelines over time.

Idioma originalEnglish (US)
Páginas (desde-hasta)121-126
Número de páginas6
PublicaciónShock
Volumen39
N.º2
DOI
EstadoPublished - feb 2013
Publicado de forma externa

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Emergency Medicine

Huella

Profundice en los temas de investigación de 'Tranexamic acid and trauma: Current status and knowledge gaps with recommended research priorities'. En conjunto forman una huella única.

Citar esto